|Other Names||Kallikrein-15, 3421-, ACO protease, KLK15|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6334a was selected from the Center region of human KLK15. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Protease whose physiological substrate is not yet known.|
|Tissue Location||Highest expression in the thyroid gland. Also expressed in the prostate, salivary, and adrenal glands and in the colon testis and kidney.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. In prostate cancer, KLK15 has increased expression, which indicates its possible use as a diagnostic or prognostic marker for prostate cancer.
Yousef, G.M., et al., J. Clin. Oncol. 21(16):3119-3126 (2003).Yousef, G.M., et al., Br. J. Cancer 87(11):1294-1300 (2002).Diamandis, E.P., et al., Expert Rev Mol Diagn 1(2):182-190 (2001).Takayama, T.K., et al., Biochemistry 40(6):1679-1687 (2001).Yousef, G.M., et al., J. Biol. Chem. 276(1):53-61 (2001).
If you have any additional inquiries please email technical services at email@example.com.